ASCO 2024: Highlights and analysis

ASCO 2024: Advances in NSCLC

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM

Osimertinib success in locally advanced EGFR-mutated NSCLC

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Adagrasib improves on docetaxel in previously treated NSCLC

Manageable safety profile with early efficacy of Tec-DR in NDMM

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer

Looking at real world evidence on PSA testing in prostate cancer

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma